PE20191549A1 - Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos - Google Patents

Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos

Info

Publication number
PE20191549A1
PE20191549A1 PE2019000822A PE2019000822A PE20191549A1 PE 20191549 A1 PE20191549 A1 PE 20191549A1 PE 2019000822 A PE2019000822 A PE 2019000822A PE 2019000822 A PE2019000822 A PE 2019000822A PE 20191549 A1 PE20191549 A1 PE 20191549A1
Authority
PE
Peru
Prior art keywords
amine
pyrimidin
pyrazole
alkyl
compounds
Prior art date
Application number
PE2019000822A
Other languages
English (en)
Inventor
Anja Giese
Jurgen Klar
Alexander Helmut Michael Ehrmann
Jens Willwacher
David Engel
Andre Philippe Dieskau
Antje Kahnert
Alexey Gromov
Carsten Schmeck
Niels Lindner
Thomas Muller
Anna Lena Andreevski
Jan Dreher
Karl Collins
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of PE20191549A1 publication Critical patent/PE20191549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

REFERIDO A COMPUESTOS DERIVADOS DE 6-(1H-PIRAZOL-1-IL)PIRIMIDIN-4-AMINA DE FORMULA (I) DONDE R1 es R1a, ENTRE OTROS, EN DONDE R5 ES HALOGENO, CN, ENTRE OTROS; R6 ES HETEROARILO DE 6 MIEMBROS, CICLOALQUILO(C4-C8), ENTRE OTROS; R7 ES H, ALQUILO(C1-C4), FENILO, ENTRE OTROS; R2 ES H, ALQUILO(C1-C4), ENTRE OTROS; R3 ES H, HALOGENO, CN, ENTRE OTROS; R4 ES H, ALQUILO(C1-C4), CICLOALQUILO(C3-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[5-(2,4-DIFLUOROFENIL)-4-ETIL-1H-PIRAZOL-3-IL]-6-(3,5-DIMETIL-1H-PIRAZOL-1-IL)PIRIMIDIN4-AMINA; 6-(4-CLORO-3,5-DIMETIL-1H-PIRAZOL-1-IL)-N-[4-CICLOPROPIL-3-(4-FLUOROFENIL)-1H-PIRAZOL-5-IL]PIRIMIDIN-4-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL TRANSPORTADOR DE Pi Npt2a SIENDO UTILES EN EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES CARDIOVASCULARES Y RENALES
PE2019000822A 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos PE20191549A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193953 2016-10-14
PCT/EP2017/075630 WO2018069222A1 (en) 2016-10-14 2017-10-09 Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PE20191549A1 true PE20191549A1 (es) 2019-10-24

Family

ID=57136772

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000822A PE20191549A1 (es) 2016-10-14 2017-10-09 Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos

Country Status (28)

Country Link
US (2) US11208400B2 (es)
EP (1) EP3526212B1 (es)
JP (1) JP2019532961A (es)
KR (1) KR20190065402A (es)
CN (1) CN110191884A (es)
AR (1) AR109947A1 (es)
AU (1) AU2017341324A1 (es)
BR (1) BR112019007496A2 (es)
CA (1) CA3040166A1 (es)
CL (1) CL2019001004A1 (es)
CO (1) CO2019003761A2 (es)
CR (1) CR20190192A (es)
CU (1) CU24518B1 (es)
DO (1) DOP2019000099A (es)
EA (1) EA201990947A1 (es)
EC (1) ECSP19026563A (es)
GE (1) GEP20217269B (es)
IL (1) IL265923A (es)
JO (1) JOP20190080A1 (es)
MA (1) MA46514A (es)
MX (1) MX2019004347A (es)
PE (1) PE20191549A1 (es)
PH (1) PH12019500808A1 (es)
SG (1) SG11201903305XA (es)
TN (1) TN2019000114A1 (es)
TW (1) TW201825477A (es)
UY (1) UY37444A (es)
WO (1) WO2018069222A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN115403524A (zh) * 2021-05-26 2022-11-29 浙江省化工研究院有限公司 3-氟代吡唑羧酸酯、3-氟代烷基-1-取代吡唑-4-羧酸的制备方法
WO2024061768A1 (en) 2022-09-19 2024-03-28 Basf Se Azole pesticidal compounds

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
US6355823B1 (en) 1999-01-21 2002-03-12 Board Of Regents, The University Of Texas System Inhibitors of intestinal apical membrane na/phoshate co-transportation
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US7119120B2 (en) 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102008020113A1 (de) * 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
CA2684240A1 (en) * 2007-04-16 2008-10-30 Serenex, Inc. Tetrahydroindole and tetrahydroindazole derivatives
JP2008296610A (ja) 2007-05-29 2008-12-11 Toyota Motor Corp 車両用動力伝達装置の制御装置
CA2720888A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
RS56312B1 (sr) 2010-02-27 2017-12-29 Bayer Ip Gmbh Ariltriazoloni spojeni sa bis-arilom i njihova upotreba
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2011272800B2 (en) 2010-06-30 2016-11-03 Cyclerion Therapeutics, Inc. sGC stimulators
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590655B1 (en) 2010-07-07 2015-06-24 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2708539A1 (de) 2010-07-09 2014-03-19 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
IN2014CN03130A (es) 2011-10-27 2015-07-03 Astellas Pharma Inc
WO2013082756A1 (en) 2011-12-06 2013-06-13 Leo Pharma A/S Phosphate transport inhibitors ii
US10150742B2 (en) 2013-03-15 2018-12-11 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
MA40893B1 (fr) 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
CN105631664A (zh) 2014-11-26 2016-06-01 华为终端（东莞）有限公司 一种非接触支付方法、装置及***
CN107406442B (zh) * 2014-12-23 2021-08-17 达纳－法伯癌症研究所公司 作为egfr抑制剂的新的嘧啶和治疗病症的方法
US10934273B2 (en) 2016-10-14 2021-03-02 Novartis Ag Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide
EP3525780B1 (en) 2016-10-14 2021-06-02 Institut Pasteur De Montevideo Pluripotent anti-inflammatory and metabolic modulators for the treatment of inflammation related conditions
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates

Also Published As

Publication number Publication date
IL265923A (en) 2019-06-30
JP2019532961A (ja) 2019-11-14
MA46514A (fr) 2019-08-21
US11208400B2 (en) 2021-12-28
BR112019007496A2 (pt) 2019-09-10
CL2019001004A1 (es) 2019-08-30
SG11201903305XA (en) 2019-05-30
US20200055842A1 (en) 2020-02-20
TN2019000114A1 (en) 2020-10-05
PH12019500808A1 (en) 2020-01-20
CR20190192A (es) 2019-09-02
CA3040166A1 (en) 2018-04-19
KR20190065402A (ko) 2019-06-11
CO2019003761A2 (es) 2019-04-30
DOP2019000099A (es) 2019-07-15
MX2019004347A (es) 2019-07-01
AU2017341324A1 (en) 2019-05-02
EP3526212A1 (en) 2019-08-21
UY37444A (es) 2018-05-31
ECSP19026563A (es) 2019-04-30
CU20190035A7 (es) 2019-11-04
EA201990947A1 (ru) 2019-08-30
EP3526212B1 (en) 2021-12-22
JOP20190080A1 (ar) 2019-04-11
US20230065629A1 (en) 2023-03-02
CN110191884A (zh) 2019-08-30
CU24518B1 (es) 2021-06-08
AR109947A1 (es) 2019-02-06
TW201825477A (zh) 2018-07-16
GEP20217269B (en) 2021-06-25
WO2018069222A1 (en) 2018-04-19

Similar Documents

Publication Publication Date Title
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20190913A1 (es) Derivados aromaticos de sulfonamida
PE20211411A1 (es) Compuestos de anillo fusionado
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20171329A1 (es) Agentes inmunorreguladores
PE20190711A1 (es) N-(fenils ulfonil) benzamidas y compuestos relacionados como inhibidores de bcl-2
UY38448A (es) Compuestos de azol-amida pesticidamente activos
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
DOP2021000038A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20160540A1 (es) Inhibidores de bromodominios
PE20161443A1 (es) Compuestos
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
EA201290260A1 (ru) Бензимидазол-имидазольные производные
PE20151072A1 (es) Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa